Undesired weight gain remains a significant concern in the United States. According to a survey conducted by the American Psychological Association (APA) and The Harris Poll, 42% of U.S. adults gained more weight than intended during the pandemic, with an average increase of 29 pounds [1]. This trend has led to an increasing demand for weight loss supplements, which is projected to have a compound annual growth rate (CAGR) of nearly 8% and a market size of over 128 billion USD by 2026 [2]. Steve Geiger, the VP/GM of Sales and Operations for Vidya Herbs USA, acknowledges the sustained demand for innovative ingredients that support weight management: “It’s clear that the demand for innovative ingredients supporting weight management isn’t going anywhere anytime soon.”
In line with this demand, Vidya Herbs continues its dedicated efforts at the company’s state-of-the-art R&D center to develop unique ingredients that product development scientists can rely on for weight management. K Shyam Prasad, Vidya Herbs' Founder and Managing Director, affirms that their commitment remains unwavering in 2023. RoseFit™, Vidya’s latest addition, joins the other clinically studied ingredients, including CGA-7™, SUNCA™, and AFPERFIT™, all of which support a healthy body weight and metabolism.
RoseFit™ sets itself apart as a groundbreaking water-soluble rose (Rosa multiflora) petal extract standardized to 60% polyphenols and 2-3% isoquercetin. Unlike many weight management ingredients that focus on traditional visual measures, like waist-to-hip ratio or percentage of body fat, RoseFit™ introduces a hormonal component. While the common approach to weight management involves targeting fat-burning mechanisms to reduce BMI or body fat, RoseFit™ addresses the upstream controls of eating. Without a balance in hormones, such as ghrelin and leptin, even a healthy diet may not prevent overeating. RoseFit™ effectively restores balance to these hormones.
A randomized, double-blind, placebo-controlled trial involving overweight adults demonstrated significant improvements among those consuming 400 mg/day of RoseFit™ for 12 weeks. The participants experienced a significant mean reduction in body weight (p<0.001), BMI (p<0.001), % body fat, and fat mass (p<0.001) compared to the placebo group (see Figures 1 through 3). The trial also included additional measures, such as serum markers and scores on a visual analogue scale (VAS). The extract group showed positive serum improvements, including a significant increase in leptin (p<0.05) and a significant decrease in ghrelin (p<0.001). Furthermore, the VAS results indicated significant favorable changes in hunger, satiety, fullness, and prospective food consumption compared to the placebo group.
RoseFit™ offers diverse applications for dietary supplements, ranging from capsules and tablets to softgels, gummies, powders, and beverages. It represents a novel approach to weight management by addressing the root causes of a patient’s concerns. Rather than providing a temporary solution, RoseFit™ offers a long-term strategy for managing weight by targeting body fat percentage, hormonal imbalances, and elevated BMI, all of which contribute to weight gain.
-----
References:
- American Psychological Association. (2021).
- Grand View Research. (n.d.). Weight Loss Supplements Market Size, Share & Trends Analysis Report By End User (18-40 Years, Under 18 Years), By Distribution Channel 2021-2028.
